KRAS and non-small cell lung carcinoma: Notably, Romidepsin has increased the sensitivity of Erlotinib synergistically in all nine NSCLC cell lines, including EGFR and KRAS wild type cell lines, KRAS mutant cell lines, and TKI resistant EGFR mutant cell lines, with this effect being partially due to enhanced apoptosis [64].